Ambea runs residential care homes for older people and people with disabilities across the Nordics, with care units for dementia, mental health and other complex needs, plus a sizeable home-care operation in Sweden. Its advantage is scale in a fragmented, publicly funded market: a national network of homes gives it purchasing and staffing leverage that smaller operators cannot match, and local-authority contracts, once won, tend to be sticky. Revenue growth of 7.3% is coming from both occupancy and new units, while the 27.9% gross margin and 7.8% operating margin show the business is thin-margin by design, so the investment case rests on volume and cost discipline rather than pricing power. At 19.3x trailing and 21.7x forward earnings the market is not pricing in a sharp earnings decline, but the forward multiple sitting above the trailing one means consensus expects earnings to dip before they recover. A 15.5% return on equity is respectable for a labour-heavy operator, so the question for the team is whether wage inflation and Swedish municipal budget pressure will compress that margin further, which is worth a deeper look at the next quarterly report.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 23 Oct 2026, 01:52 CEST | ACCE price target | kr 205 | first publication | kr 183 |
| 22 Oct 2026, 14:04 CEST | Rating | Undervalued | first publication | kr 183 |
| 22 Oct 2026, 14:04 CEST | Fair value | kr 217 | first publication | kr 183 |
Answered from Ambea AB (publ) fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| AMBEA.ST Ambea AB (publ) | kr 181.80 | kr 217 | 16% below | 19.1x | 15.5% | 47 | 68 |
| SIA.TO Sienna Senior Living Inc. | C$20.53 | C$11 | 86% above | 38.7x | 6.7% | 42 | 50 |
| ATT.ST Attendo AB (publ) | kr 114.80 | kr 135 | 15% below | 16.9x | 18.7% | 52 | 63 |
| ARDT Ardent Health Inc. Common Stock | $12.27 | $16 | 25% below | 22.7x | 10.0% | 47 | 53 |
| AMN AMN Healthcare Services Inc | $48.01 | $71 | 33% below | 17.9x | 15.6% | 52 | 73 |
| ASTH Astrana Health Inc. Common Stock | $37.45 | - | - | 44.7x | 6.9% | 35 | 72 |
| SGRY Surgery Partners Inc. Common Stock | $15.75 | $10 | 52% above | - | 2.3% | 33 | 43 |
Where AMBEA.ST ranks against its sector peers on each metric.